New early-stage study of aducanumab adds to arsenal of strong data in Alzheimer's

3 November 2017

US biotech major Biogen (Nasdaq: BIIB) is touting new data from the long-term extension (LTE) of its ongoing Phase Ib study of aducanumab, the company’s investigational treatment for Alzheimer’s disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting, Boston, November 1 – 4.

The data include results from patients in the Phase Ib study who were treated with a gradually increased dose of aducanumab for up to 24 months and those who were treated with a fixed dose of 3, 6 or 1mg/kg aducanumab for up to 36 months.

The results are consistent with previously reported analyses from the Phase Ib study and support the design of the ongoing Phase III studies of aducanumab for early Alzheimer’s disease, said Eisai. Phase III data for aducanumab is expected in late 2019 or early 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK